More recently, our understanding of the pathophysiology of T2DM has been further aided by the discovery of novel disease biomarkers where high blood concentrations of proinflammatory cytokines, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor (TNF) are associated with an increased risk of T2DM [6] . The gene discussed is TNF; the disease is type 2 diabetes mellitus.